Consumer Driven Health Care

Sens. Tim Kaine and Mark R. Warner, who both have championed to lower the cost of prescription drugs, applauded Sanofi, Novo Nordisk and Eli Lilly – the three major insulin manufacturers – for slashing prices, effective Jan. 1, 2024.

Due to a nationwide shortage of therapists, about a third of U.S. employers say they offer employees AI-based wellness and mental health programs, yet researchers say there isn't enough evidence that the programs work.

The Food and Drug Administration approved 55 new treatments in 2023, representing a nearly 50% increase from the year before, with Pfizer gaining the highest number of high-profile approvals covering a wide range of illnesses.

Health and retirement benefits are more important now than they've ever been as employers compete for top talent, with employees' mental health now taking a more prominent place in a company's benefits package.

Despite the Biden administration's numerous initiatives to crack down on the high cost of drugs, several big drugmakers will hike prices this month, with Pfizer announcing over a quarter of the increases.

After the Federal Trade Commission sent warning letters to 10 drugmakers over 100 "improper" patents, 3 chose to delist their patents from the FDA's registry, potentially accelerating the approval of generic versions.